Find information on thousands of medical conditions and prescription drugs.

Eprosartan

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten® by the Biovail Corporation in the United States and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide. more...

Home

E-Base

Edecrin

Effexor

Elavil

Elidel

Eligard

Elitek

Elmiron

Elspar

Emtriva

Endep

Enulose

Epi-pen

Epinephrine

Epirubicin

Epitol

Epivir

Epogen

Eryc

Eryped

Esgic

Esmolol

Estrace

Estring

Estrone

Evista

Exelon

Exemestane

Hexal Australia

The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT₁ receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than ACE inhibitors, especially among the elderly.

Read more at Wikipedia.org

• [List your site here Free!]


		Eprosartan Monograph


	ARB outperforms calcium antagonist in secondary stroke prevention The angiotensin receptor blocker, eprosartan, is associated with fewer adverse cardiovascular/cerebrovascular events, compared with the calcium antagonist, ... From Geriatrics, 4/1/05

	Moses Trial Shows TEVETEN — Eprosartan — Reduces Risk Of Second Stroke in Hypertensive Stroke Patients; Results Presented at European Society TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that a major cardiovascular study has shown that TEVETEN(R) (eprosartan), an angiotensin ... From Business Wire, 9/2/04

	Biovail Acquires Rights to Novel Formulations of Eprosartan and Carvedilol Business Editors TORONTO--(BUSINESS WIRE)--Feb. 26, 2004 Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today it has acquired the rights to a ... From Business Wire, 2/26/04

	Fda Approves Biovail's Teveten Hct For Hypertension Biovail Corporation (NYSE:BVF)(TSX:BVF), Toronto, has announced that the United States Food and Drug Administration (FDA) has approved Teveten(R) HCT ... From Worldwide Biotech, 4/1/03

	Irbesartan-associated persistent edema of the eyelids, face, and neck - Case Reports Abstract Irbesartan, an angiotensin II receptor antagonist (AIIRA), is an antihypertensive agent that inhibits the activity of angiotensin II by selectively ... From Journal of Drugs in Dermatology, 12/1/02 by Philip R. Cohen

	Antihypertensive Agents and Cytochrome P450 Interactions Many patients with hypertension must use more than one antihypertensive medication to achieve blood pressure control. Drug interactions are possible, ... From American Family Physician, 6/1/02 by Richard Sadovsky

	Angiotensin receptor blockers not equivalent to ACE inhibitors for heart failure - Patient-Oriented Evidence that Matters Jong P, Demers C, McKelvie RS, Liu PP, Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol ... From Journal of Family Practice, 6/1/02 by James G. Slawson

	Fda Approves Androgel To Treat Male Testosterone Deficiency Unimed Pharmaceuticals, Inc., Buffalo Grove, Ill., has announced that AndroGel(TM) 1% (testosterone gel) (C-III) has been approved by the U.S. Food and Drug Administration (FDA). The approval makes From Worldwide Biotech, 4/1/00

Home

Contact

Resources

Exchange Links

ebay